Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegoprazan - HK inno.N/RaQualia Pharma

Next Previous
Drug Profile

Tegoprazan - HK inno.N/RaQualia Pharma

Alternative Names: BLI-5100; CJ-12420; IN-A001; K-CAB; K-CAB-Tablet ; LXI-15028; RQ-00000004; RQ-4; Tegoprazan Tablet 12.5 mg

Latest Information Update: 14 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer CJ Cheiljedang Corp.; HK inno.N; RaQualia Pharma; Sebela Pharmaceuticals; Shandong Luoxin Pharmaceutical
  • Class Amides; Anti-inflammatories; Antibacterials; Antiulcers; Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • Phase III Duodenal ulcer; Gastric ulcer; Helicobacter infections; Peptic ulcer

Most Recent Events

  • 07 Aug 2025 Sebela Pharmaceuticals plans to file an NDA with the FDA for Erosive Esophagitis (EE) and Non-Erosive Reflux Disease (NERD) in Q4 2025.
  • 07 Aug 2025 Efficacy and adverse event data from phase III TRIUMPH trial in Erosive oesophagitis released by Sebela Pharmaceuticals
  • 07 Aug 2025 Efficacy and adverse event data from phase III TRIUMPH trial in Gastro-oesophageal reflux released by Sebela Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top